Zydus partners with Myriad Genetics to launch cancer diagnostic tests in India

Marquee JV announcedStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹911.00

prior close

₹923.20

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.6%+0.4% vs market

Pharmaceuticals peers, median of 153sector+0.6%+0.3% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

-0.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.6+0.4+0.6+0.3

Next day

+0.7+1.4-0.7+1.3-0.6

+2.0+1.5+0.5+1.4+0.6

+0.7+1.3-0.7+1.4-0.8

+0.1+1.0-0.9+0.7-0.7

-0.8+0.6-1.4+0.0-0.8

+0.3+1.4-1.1+0.7-0.4

15d

-1.5+0.1-1.7-1.0-0.5

-3.6-0.5-3.0-1.8-1.7

-1.1-0.9-0.2-4.0+3.0

-3.5-10.2+6.6-10.2+6.7

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has signed an exclusive agreement with US-based Myriad Genetics to launch three precision cancer diagnostic tests in India: MyRisk (63-gene hereditary cancer test), MyChoice HRD Plus for ovarian cancer, and Prolaris for prostate cancer. Zydus will exclusively market, create clinician awareness, and drive adoption of these globally validated tests across Indian hospitals and clinics. No financial terms disclosed.

Likely market impact

Expands Zydus into precision oncology diagnostics, complementing its pharma business. Positive for long-term growth, though deal size is undisclosed.